DTC websites

Neurocrine Talk About TD

Website for the launch of Neurocrine’s “Talk About TD” disease education campaign, driving broader awareness of tardive dyskinesia (TD) within the United States. This campaign inspires patients and caregivers to be proactive participants in their healthcare regimen. Instead of merely joining the conversation about TD, they can feel empowered and equipped to confidently discuss TD with their healthcare providers.

Highlights of this website include stories from real people affected by TD, suggestions for caregiver support, and a robust resources page with 20+ online tools, guides, and support groups. Concepted, researched, wrote, revised, fact-checked, referenced, annotated, and obtained regulatory approval.

Ultragenyx launch website

Launch website for Ultragenyx’s Mepsevii, the first and only treatment approved for patients with Mucopolysaccharidosis VII (MPS VII). MPS VII is a progressive disease caused by the chronic accumulation of GAGs, which Mepsevii helps to recycle.

This website uses a personable, straightforward voice in order to provide clarity and reassurance for patients and their caregivers. The tone strikes a balance between serious and hopeful, capturing the optimism of Mepsevii’s potential while being mindful of the gravity of the disease. Concepted, researched, wrote, revised, fact-checked, referenced, annotated, and obtained regulatory approval.

Neurocrine branded website

Award-winning launch website for Neurocrine’s Ingrezza, the first FDA-approved treatment for adults with tardive dyskinesia (TD). The “Less TD, More of Me” campaign captures the ultimate goal of helping TD patients feel less like their condition and more like themselves. Rather than succumbing to the despair and frustration caused by their uncontrollable movements, patients are encouraged to take charge of their condition.

The Ingrezza patient website brings all of the available TD resources to light in an engaging, accessible platform, including disease education, medications, brochures, support programs, and advocacy groups. By distilling high science into patient-friendly language, both the condition and its treatment become less daunting. Researched, co-wrote, revised, fact-checked, referenced, annotated, and obtained regulatory approval.

BioMarin launch website

Launch website for BioMarin’s Vimizim, the first and only enzyme replacement therapy for people with Mucopolysaccharidosis IVA (Morquio A). Morquio A syndrome is a rare, severely debilitating and progressive disease that previously had no approved, standard-of-care treatment other than palliative care.

This website guides users through key facts about the causes, symptoms, and progression of Morquio A, and explains how Vimizim works to help replace the deficient GALNS in Morquio A patients and reduce the buildup of GAGs. Researched, co-wrote, revised, fact-checked, referenced, annotated, and obtained regulatory approval.